Recently, a large retrospective analysis of HR changes during crizotinib therapy among patients with ALK‐positive NSCLC enrolled in the PROFILE 1005 and PROFILE 1007 clinical trials was analyzed [5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.